Skip to content
CharitiesAidWelfare, Medical Health Aged Care

A rare cancer. A death sentence.

Leukaemia Foundation 4 mins read

Leukaemia Foundation calls for urgent action for the rare blood cancer, acute myeloid leukaemia.

 

This Rare Cancers Awareness Day (26 June), the Leukaemia Foundation is calling for greater awareness and urgent investment in research to tackle one of the deadliest[i] and under invested rare cancers in Australia – acute myeloid leukaemia (AML).

 

While more than 120 types of blood cancer are individually considered rare, AML stands out for all the wrong reasons: it is fast, aggressive, and survival rates have barely improved in over two decades[ii].

 

According to Leukaemia Foundation CEO, Chris Tanti, “AML is not just rare – its ruthless.”

 

“We’ve seen incredible progress in the treatment and survival for some blood cancers, but comparatively AML has been left behind,” Mr Tanti said.

 

“The harsh reality is, if you’re diagnosed with AML, there’s an 80 per cent chance you won’t survive[iii]. That’s not just unacceptable – it’s unthinkable in 2025.” 

 

Despite accounting for just 6% of all blood cancer diagnoses, AML causes more than 20% of blood cancer-related deaths[iv].

 

It impacts people of all ages – from children to older adults – and its symptoms often appear suddenly and progress rapidly, leaving little time for intervention. 

 

"Right now, AML is a near-certain death sentence for far too many Australians. Sadly, one in two people won’t survive twelve months from their diagnosis[v].    

 

“And the truth is – we don’t have the answers – yet. But research, improved awareness and increased support for patients can help change the dial.

 

“We need to stop treating rare blood cancers like they’re rare problems. They’re real. They’re deadly. And they deserve urgent attention.”

 

The statistics on AML speak volumes: 

  • For children, one in four will not survive beyond five years[vi]
  • For adults, that number is three in four[vii]

 

AML is also the second most common cancer in children under 15, and among the top three causes of childhood cancer deaths in Australia[viii]. 

 

Fuelling the issue, is that from the time you present to a doctor, AML can take up to two to three months to diagnose[ix], drastically impacting treatment options and survival outcomes.

 

“Too many Australians are falling victim to AML. And while you can’t screen for it, or you can’t prevent it, there is something you can do – know the signs to help enable an earlier diagnosis,” Mr Tanti said.  

 

“Ongoing fatigue, frequent infections, unexplained bruising, bleeding or weight loss, and swollen lymphoma nodes are common symptoms of AML.

 

“By spotting these early, you could increase your chance of survival by up to 30 per cent[x].”

 

The Leukaemia Foundation however believes the most critical step to reversing the impact of AML is greater investment in blood cancer research focused on early detection and treatment, and more support for patients.

 

“Since 2000, the Leukaemia Foundation has invested more than $87 million in blood cancer research, with most of our current research investment focused on AML.

 

“We’re proud to be backing some of Australia’s best and brightest researchers who are working on tomorrow’s answers, whilst standing beside families who critically need our help today.

 

“With the right investment, we believe we can rewrite the future for people with AML. But without it, the story stays the same – and too many lives will be lost.”

 

The Australian Academy of Science and the Australian Academy of Health and Medical Sciences have both echoed the call for urgent investment through the Blood Cancer Research Roadmap. Without it, AML survival rates will continue to lag. 

 

The Leukaemia Foundation is urging Australians to donate to support life-saving research and vital services for families facing AML and other blood cancers via its tax appeal.

 

“Beloved Australian Magda Szubanski’s recent diagnosis has reminded us that blood cancer can strike anyone, at any time. And whilst her diagnosis is also rare, the grief it causes is all too common,” added Mr Tanti.

 

“That’s why we’re calling on Australians to back our research, support our services, and help give people with AML, and all blood cancers, a fighting chance.”

 

To donate to the Leukaemia Foundation’s tax appeal, or learn more about AML and blood cancer, visit www.leukaemia.org.au 




About us:

About the Leukaemia Foundation: The Leukaemia Foundation stands with Australia to help cure and conquer blood cancer – with care. Together we are attacking every blood cancer, from every direction, in every way we can. We stand beside every Australian to be their voice and their someone-to-turn to, fighting to get them access to the best care. We also accelerate research that is delivering rapid advancements in blood cancer diagnosis and treatments. Plus, we provide services and support that empower people living with any blood cancer to live well after diagnosis. You can learn more about the Leukaemia Foundation and blood cancer at leukaemia.org.au


Contact details:

Please contact the Leukaemia Foundation media team on [email protected] or call 0473 154 079. 

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.